Intravenous Apresoline is a powerful renal vasodilator in cardiac as well as in noncardiac patients. In hypertensive patients in congestive heart failure, the drug produces a striking improvement in both cardiovascular and renal function. The increases in renal plasma flow are inconsistently related to changes in arterial pressure and cardiac output Unlike many, hypotensive drugs, Apresoline usually causes no decrease in the renal excretion of sodium and water. Circulatory collapse produced by the drug may occur in the presence of an increased cardiac output but is accompanied by a deterioration of the arterial pressure pulse and a reduction in sodium and water excretion.
P REVIOUS REPORTS'-3 have shown that the acute administration of hydralazine* (Apresoline), a hypot ensive agent, produces marked increases in renal blood flow in normal man as vell as in patients with compensated hypertensive disease. Wilkinson and co-workers3 have measured cardiovascular and renal hemodynamic function (but not simultaneously) in normal and hypertensive patients, and found that the acute administration of Apresoline increases not only the renal blood flow but also the cardiac output. These hemodynamic responses are strikingly different from those caused by other hypotensive agents such as dihydroergocornine (DHO), veratrum, and hexamethonium which in coImpensated hypertensive patients usually decrease (at least, transiently) the renal blood flow and the sodium and water excretion without appreciably (changing the cardiac output. To determine Xvhether a fall in arterial pressure when associated vith a rise in cardiac output and renal plasma flow might, be accompanied by a rise in sodium and water excretion, it was decided to study the effect of intravenous Apresoline on electrolyte and water excretion as well as on cardiovascular and renal hemodynamic function.
PA.kT1 ENTS Twelve patients with essential hypertension without heart failure were studied; eight with normal hearts and four with hypertensive heart (lisease. Thoracolumbar sympatheectomvlhad been previously performed in two of these patients (V. V., S. 0). Ten patients were studied with valvular or nonvalvular heart disease and pulmonary hypertension including three (A. A., S. E., I. G.) with hypertensive cardiovascularldisease and severe congestive failure and marked pelripheral edema. Five had rheumatic heart disease with mitral stenosis or insufficiency without peripheral edema, and two (L. N, 0. I.) had iight ventricular failure as indi-(ated by elevation of the right ventricular end (liastolic pressure. Four l)atients had chronic l)ulnonary disease (emphysemiia) with mild to moderate pulmonary hypertension, but no peril)heral edemia or other clinical signs of right heart failure.
None of the compensate(l hypertensive patients had been on a low sodium diet or antihypertensive (Irug therapy. for at least three months pIior to the JUI)S()N, HOLLANI)EIR AND) WI L ISINS failure had been treated prior to the study with digitalis or diuretics. The two patients (0. I., L. N.) with atrial fibrillation were taking digitalis daily and were on a restricted sodium diet. Patient L. U. was also on a low sodium diet. With Since the changes in oxygen consumption were slight, the increases in cardiac output in the different groups were associated with a narrowing of the arteriovenous oxygen differences. The most striking decrease in the arteriovenious oxygen difference (8.36 volumes per 100 ml.) oc(urred in patient S. E. who had hypertensive (cardiovrascular disease and severe congestive heart failure.
Vascicdar Pre.ssies Pulmonarly Arterial Pressure. In the hypertensive patients without heart failure, the mean pulmonary arterial pressure increased slightly or not at all after intravenous Apresoline, the average rise being 2 mm. Hg. In the group with cardiac insufficiency the changes in pulmonary arterial pressure, although definite in different cases, wvere inconsistent. In the patients with hypertensive cardiovascular disease and congestive heart failure (A. A., S. E.) reductions of 3 and 17 mm. Hg occurred in the mean pulmonary arterial pressure. These decreases were associated with marked increases in cardiac output. In contrast, patients with valvular heart disease, including those who had vascular collapse, usually had increases in pulmonary arterial pressure associated with rises in cardiac output. Patients with chronic lung disease had similar rises in pulmonary arterial pressure, the average increase being 7 mm. Hg. Right Ventricular End Diastolic Pressure. In the compensated hypertensive patients the changes in measured right ventricular end diastolic (R.V.D.) pressure were slight and inconsistent. However, in patients with mitral valvular heart disease, including those who had circulatory collapse ( fig. 2) , and in patients with chronic lung disease the right ventricular end diastolic pressure usually increased from 1 to 7 mm. Hg. In contrast, the hypertensive patients with congestive heart failure had appreciable decreases in the right ventricular end diastolic pressure ranging from 3 to 10 mm. Hg.
Arterial Pressure. The reductions in mean arterial pressure after intravenous Apresoline were comparable in both the compensated hypertensive and cardiac insufficiency groups. The fall in blood pressure, however, in patients with chronic lung disease was less impressive.
The marked reductions in blood pressure in three patients (L. 0., L. M., L. U.) with mitral stenosis and in one (0. O.) with compensated hypertensive disease were associated with circulatory collapse. During this hypotensive state the arterial pressure pulse was low and flat, and the reflected dicrotic wave had disappeared.
Heart Rate
After intravenous Apresoline, the heart rate increased to a comparable degree in all three groups with the exception of the hypertensive patients in congestive failure.
Vascular Resistances
In all except the twvo hypertensive patients with congestive failure, the average change in the "total pulmonary" resistance was slight. However, in these two patients the "total pulmonary" resistance decreased markedly.
With the reduction in the arterial pressure and associated increase in cardiac output in the different groups the total peripheral resistance fell appreciably. The In the three patients with mitral stenosis who developed vascular collapse the glomerular filtration rate usually fell below the previous high (post-Apresoline) level, but not below the control (pre-Apresoline) value with the exception of patient L. M.
Electrolyte and Water Excretion
The control sodium and water excretion in the hypertensive group (without heart failure) was considerably higher than the control values in the cardiac and chronic pulmonary disease groups. Following intravenous Apresoline the changes in sodium and water excretion in the hypertensive group, with the exception of patient 0. 0., were slight and inconsistent ( fig. 3) . The average change in the group was negligible.
In contrast, the sodium and water excretion in the cardiac insufficiency group usually increased. The most impressive increases in sodium and water excretion in this group occurred in hypertensive patients in congestive heart failure and were associated with appreciable increases in glomerular filtration rate and renal plasma flow ( fig. 1) . The increase in sodium excretion in these patients ranged from 349 to 826 microequivalents per minute.
The excretion of sodium and water after intravenous Apresoline was strikingly reduced in the patients who developed circulatory collapse, with the exception of patient L. U. in whom the excretion of sodium and water was very low even during the control period. In patient L. 0., although the sodium and water excretion fell below the control level, the glomerular filtration rate did not.
In general, potassium excretion varied in the same direction as did the glomerular filtration rate. The average increase in potassium excretion in the hypertensive group without heart failure was 7 per cent; in the cardiac insufficiency group, 81 per cent; and in the chronic lung disease group, 36 per cent.
The Effects of Intravenous Apresoline during
Acute Reductions in Renal Excretion of Sodium and IPater Since it appeared that intravenous Apresoline caused marked increases in sodium, potassium, and water excretion in decompensated hypertensive patients who were chronically retaining sodium and water as manifested by peripheral edema, it seemed possible that this drug might prevent or correct acute reductions in salt and water excretions such as may be produced by cuff congestion of the limbs or intravenous injection of hexamethonium. Its effect during acute renal retention of sodium and water was therefore studied in four compensated hypertensive patients. In three of these patients (S. O., R. O'D., M. R.) a reduction in sodium and water excretion had been induced by decreasing the effective blood volume with congesting cuffs on the thighs. The cuffs were Patients with valvular heart disease tended to have smaller increases in cardiac output after Apresoline than patients without this disorder. It seems probable that greater increases in cardiac output did not occur in these patients mainly because of the mechanical disturbance in blood flow through the heart caused by the damaged valves. A mechanical interference with flow may likewise explain in part the higher incidence of circulatory collapse in patients with mitral stenosis. It is possible that if blood flow through the stenotic mitral orifice had not been impeded, a larger increase in cardiac output might have helped to maintain the blood pressure and prevent collapse. The finding of an increased cardiac output during collapse after Apresoline indicates that a reduction in cardiac output does not necessarily signal this state. A marked reduction in arterial pressure associated with an advanced deterioration of the arterial pressure pulse may be a more reliable signal of circulatory collapse.
Unlike patients with valvular heart disease and chronic pulmonary disease, hypertensive patients in congestive heart failure had reductions in the pulmonary arterial and intracardiac pressures with the increase in cardiac output. It appears not unlikely that the former changes resulted from a more efficient emptying of the left ventricle, as suggested by a reduction in the "wedge" pressure or "pulmonary capillary" pressure in patient A. A. from 40 to 35 mm. Hg. The improved emptying and increase in left ventricular stroke output may primarily be dependent upon a lowering of the systemic arterial pressure and peripheral resistance. However, Apresoline might also have improved cardiac function by stimulating directly or indirectly the myocardium. The improvement in cardiovascular function in hypertensive patients in congestive heart failure has also been reported following the administration of other hypotensive drugs, such as hexamethonium (5) and veratrum (6) .
Unlike many hypotensive agents such as veratrum, dihydroergocornine and hexamethonium, intravenous Apresoline usually caused no decrease in the renal excretion of sodium and water in compensated individuals. The maintenance of sodium and water excretion during a reduction in blood pressure suggests the possibility that acute changes in blood pressure per se do not regulate the excretion of sodium and water, but that an associated renal hemodynamic change or changes may regulate these functions. Sodium amytal7 and reserpine8 are two other hypotensive agents which reduce blood pressure without usually altering sodium and water excretion. They, like Apresoline, differ from hypotensive drugs which reduce sodium and water excretion in that they do not reduce the renal plasma flow.
Although a reduction in blood pressure per se may not be a stimulus for the renal retention of sodium and water, a critical reduction with associated collapse changes in the arterial pressure pulse may cause such responses. This possibility was suggested in three patients who had reductions in sodium and water excretions following a marked fall in arterial pressure and the development of a collapse type of arterial pressure pulse. Although other hemodynamic factors (cardiac output, pulmonary arterial and right ventricular pressures) may have operated to reduce sodium and water excretion in these patients, they were not identifiable from the hemodynamic measurements obtained. Apresoline had a pronounced effect on the renal excretion of sodium, potassium, and water in hypertensive patients in congestive heart failure. The increases in sodium excretion ranged from 349 to 826 microequivalents per minute and were associated with both an improvement in cardiovascular and renal hemodynamic function. The increases in glomerular filtration rate were of such magnitude that they alone could account for the striking increases in the electrolyte and water excretion. Although alterations in renal tubular function might likewise have contributed to these changes, there was no evidence in the cuff congestion experiments to suggest that Apresoline interfered with the renal tubular reabsorption of sodium and water. It is possible that the striking improvement in renal function and increase in the excretion of electrolytes and water in hypertensive patients in congestive heart failure may be produced not 674EIVFiCTS OF APRESOL1NEl ON CARD)IOVASCUIAR AN 
